当前位置: X-MOL 学术Bioorg. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes
Bioorganic & Medicinal Chemistry ( IF 3.3 ) Pub Date : 2021-02-13 , DOI: 10.1016/j.bmc.2021.116071
Suresh Pola 1 , Shailesh R Shah 2 , Harikishore Pingali 3 , Pandurang Zaware 3 , Baban Thube 3 , Pankaj Makadia 3 , Hoshang Patel 3 , Debdutta Bandyopadhyay 3 , Akshyaya Rath 3 , Suresh Giri 3 , Jitendra H Patel 3 , R K Ranvir 3 , S R Sundar 3 , Harilal Patel 3 , Jeevan Kumar 3 , Mukul R Jain 3
Affiliation  

The ever-growing prevalence of Type-2 diabetes in the world has an urgent need for multiple orally effective agents that can regulate glucose homeostasis. G-Protein coupled receptor 119 (GPR 119) agonists have demonstrated the glucose-dependent insulin secretion and showed beneficial effects on glycemic control in humans and/or relevant animal models. Herein, we describe our efforts towards identification of a potent and oral GPR 119 agonist 13c (ZY-G19), which showed in vitro potency in the cell-based assay and in vivo efficacy without exerting any significant signs of toxicity in relevant animal models.



中文翻译:

发现用于治疗 2 型糖尿病的有效 G 蛋白偶联受体 119 激动剂

世界上 2 型糖尿病的患病率不断增加,迫切需要多种口服有效的药物来调节葡萄糖稳态。G-蛋白偶联受体 119 (GPR 119) 激动剂已证明葡萄糖依赖性胰岛素分泌,并在人类和/或相关动物模型中显示出对血糖控制的有益作用。在此,我们描述了我们为鉴定有效的口服 GPR 119 激动剂13c (ZY-G19)所做的努力,其基于细胞的测定中显示出体外效力和体内功效,而在相关动物模型中没有表现出任何显着的毒性迹象。

更新日期:2021-02-18
down
wechat
bug